To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

March 20, 2018

Today's Rundown

Featured Story

Midstage success prompts Arena to push bowel disease drug etrasimod into phase 3

Topline data show that Arena Pharmaceuticals' ulcerative colitis candidate, etrasimod, beat out placebo in a phase 2 trial, giving it the confidence to move into phase 3.

Top Stories

Kerrisdale targets Proteostasis’ ‘ineffective’ cystic fibrosis drug in latest short attack

Kerrisdale Capital has fixed on cystic fibrosis biotech Proteostasis Therapeutics in its latest attack. The short seller launched the assault after seeing shares in Proteostasis rise 200% in three months on the back of data from a small midphase trial and the receipt of an FDA breakthrough tag.

Medicxi founds biotech creation engine C21Med

Medicxi has created an “ideas factory” to boost its capacity to turn early-stage science into pipelines of drug candidates and startups to develop them. The VC fund is setting up the venture with its CSO, David Grainger, Ph.D., and Johnson & Johnson’s Richard Mason. 

[Sponsored] Digital R&D: Emerging technologies can boost clinical development

Clinical development has fallen behind in adopting digital technologies. While digital transformation can be a complex undertaking, the rewards are well worth the effort. The time for biopharma R&D to act is now. Learn more.

Ocugen preps dry eye disease drug for phase 3

Eye disease specialist Ocugen remains on course to have two drugs in late-stage testing before the end of the year as its dry eye disease candidate OCU310 clears a phase 2 trial.

Anti-aging outfit Unity bags $55M and looks to the clinic

Unity Biotechnologies, which focuses on eliminating senescent cells to treat age-related diseases, will use the new funds to take its osteoarthritis drug into the clinic.

Anti-flu drug exploits weakness in H3N2 strain

A research team led by the University of California at San Diego has developed a small molecule that they believe could weaken or even stop the virulent H3N2 strain of flu in its tracks. It works by exploiting a flaw in the mechanism the virus uses to replicate.

Ex-IQVIA executive takes the reins at patient recruitment specialist Clinerion

Clinical trial patient recruitment expert Clinerion has been on a network expansion spree recently, and it has just tapped a new CEO with big CRO experience to help build its global patient access from 180 million to 310 million by the end of this year.

Resources

[Whitepaper] Compliance Certificate and Training for Life Sciences Professionals

4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics.

[Whitepaper] Medical Device Innovation: Are You Outrunning The Competition?

The competitive landscape in medical device R&D is tough. And simply investing in R&D is no guarantee for profitability. So how do you accelerate time-to-market?

[Webinar] Driving Market Access through Patient Advocacy: Trends & Opportunities

There’s no magic bullet to successful access but insights from patient advocates and industry experts can help shape future strategies. Learn how in this webinar. Sign up now!

[Whitepaper] CFO's, Is This Part Of Your Corporate TO DO List?

Employee stock option trading & administration, Restricted stock transactions (Rule 144), Affiliated trading plans (10b5-1), Directed share plans, Equity comp plan administration — private to public

[Whitepaper] Choosing the Right Solution: Improving the Site Feasibility Process

Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals.

[Whitepaper] How Do Sponsors Ensure Quality in Global Clinical Trials?

Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives.

[Webinar] Validating a 7 Day Membrane Filtration Sterility Test using Celsis®

Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols.

[Infographic] Evolution of Flexible Commercial Biologics Manufacturing

Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility.

[eBook] Developing Site-specifically Modified ADCs: Using a Chemoenzymatic Approach

Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology.

[Article] Optimizing titer and use of a specific enzyme for generating a fully processed antibody

Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing.

[Webinar] Within-Subject Clinical Trials: Intro to New Methods & Stat. Models

In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods.

Events

.